Name: U-Blot® Research Grade Abrezekimab
SKU: WA1013
Price: 9999 USD
Availability: InStock

U-Blot® Research Grade Abrezekimab

Ucallm.jpg

$9,999.00

Size

100ug

50ug

Clear

SKU: WA1013-50

Enter the quantity you would like, or drag the panel to find the quantity and price that best for you

Bulk Quote Authorize OEM & ODM

Product details

Background：Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).

Specifications

Target	IL13
Reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
MW(Calculated)
MW(Observed)
Host Species	Humanized
Isotype	Fab-G1-kappa
Conjugate/Modification
Modification
Recommended Dilution Ratio
Composition	0.01M PBS, pH 7.4.
Purification Process	Protein A/G purified from cell culture supernatant.
Purity	>95% as determined by SDS-PAGE.
Storage Condition	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Concentration
Clonality	Monoclonal
Clone Number
Immunogen	Mammalian Cells
Gene Name
Protein Name
Alias	IL13, NC30, Interleukin-13, IL-13
Species
Gene ID-1	P35225
Uniprot
Species.1
Gene ID
Uniprot.1
Species.2
Gene ID.1
Uniprot.2
Organism-4
Gene ID-4
SwissProt-4
Description	Background：Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).<br>
Cellular Localization
Tissue Expression
Signaling_pathway
Research Areas
Function